Shilpa Medicare IBRUSHIL for treatment of leukaemia EP News Bureau May 28, 2020 Earlier it had launched Lenvatinib ‘LENSHIL and Dasatinib ‘DASASHIL’ in the India market
Shilpa Medicare launches cancer drug at monthly therapy cost of Rs 6,440 Press Trust of India Apr 27, 2020 Shilpa Medicare has launched the Indian branded generic of Dasatinib, an anti-cancer drug with a brand name Dasashil